The Protein Aggregation & Stability conference at PEGS Europe seeks to highlight the importance in prediction of aggregation propensity affecting stability of solutions and formulations, while exploring new and advanced technologies, strategies and device design to characterize, control and mitigate aggregation.
ADVANCED STRATEGIES & TECHNOLOGIES IN PARTICLE ANALYTICS
KEYNOTE PRESENTATION: Closing the Analytical 0.1-2 Micron-Size Gap: Why, When and How?
Wim Jiskoot, PhD, Professor, BioTherapeutics, Leiden University
Chemometrics and Advanced Data Analytics for Particle Analytics
Jonas Hoeg Thygesen, PhD, Area Specialist, R&D Microanalysis, Novo Nordisk Pharmatech A/S
Monitoring and Characterizing Aggregation Variants in Co-Formulated Biologic Products: Utilizing 2D Chromatography to Assess Aggregation
Mark Anthony Haverick, PhD, Associate Principal Scientist, MSD
Solution NMR Assessments of Therapeutic Protein Behavior
Mark McCoy, PhD, Principal Scientist, Discovery Chemistry, MSD
ADVANCES IN DEVICE DESIGN TO MINIMISE AGGREGATION
New Design of a Blast Freezer Thawer to Minimize Freeze-Thaw Associated Protein Aggregation
Karoline Bechtold-Peters, PhD, Senior Strategy and Technology Leader, Biologics Technical Development & Manufacturing, Novartis Pharma AG
PREDICTION OF AGGREGATION PROPENSITY
Progress in High Throughput Biophysical Characterization Approaches to Predict Long-Term Physical Stability of Protein Drugs in Pharmaceutical Formulations
Gerhard Winter, PhD, Professor, Pharmacy, Pharmaceutical Technology and Biopharmaceutics, Ludwig-Maximilians-Universitat
Thermodynamic Prediction of the Concentration-Dependence of Protein Solutions
Thomas Laue, PhD, Professor Emeritus, Biochemistry, and Molecular Biology; Director, Biomolecular Interaction Technologies Center (BITC), University of New Hampshire
A Mechanistic Approach for the Assessment of Protein Aggregation Propensity in Therapeutic Proteins: Practical Applications in Biopharmaceutical Drug Candidate Selection and Pre-Formulation Development
Danny K. Chou, PharmD, PhD, President, Compassion BioSolution, LLC.
* The program is subject to change without notice, due to unforeseen reason.